Silver Book Fact

t-PA cost savings

The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means that t-PA saves $6,074 and adds 0.75 QALY per use.

Johnston, SC. The Economic Case for New Stroke Thrombolytics. Stroke. 2010; 41(10): S59-62. http://stroke.ahajournals.org/cgi/content/short/41/10_suppl_1/S59

Reference

Title
The Economic Case for New Stroke Thrombolytics
Publication
Stroke
Publication Date
2010
Authors
Johnston, SC.
Volume & Issue
Volume 41, Issue 10
Pages
S59-62
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Adjusted-dose warfarin reduced stroke risk in AFib patients
    Meta-analysis of randomized trials found that adjusted-dose warfarin reduced stroke risk in atrial fibrillation patients by 60%. Antiplatelet agents reduced risk by 20%.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…